CHA Medical Group

CHA Medical Group is internationally recognized as one of the pioneers of stem cell research and regenerative medicine. Through decades of scientific innovation, the group has achieved numerous world-first and Korea-first milestones in cellular therapy, reproductive medicine, and regenerative healthcare.

Key Stem Cell Research Milestones
Conducted Korea's first clinical trial using embryonic stem cell-derived therapy for retinal disease.
Successfully treated cerebral palsy using donor cord blood stem cells for the first time in the world.
Established stem cell lines derived from adult somatic cells for the first time globally.
Developed genetically modified human embryonic stem cell technologies.
Successfully performed consecutive cord blood stem cell transplants for adult leukemia patients.
Conducted Korea's first approved embryonic stem cell therapy for Stargardt's disease.
Published Asia's first clinical research paper on embryonic stem cell-derived treatment for retinal disease.
Established cloned stem cell lines using adult somatic cells, a world-first achievement.
Developed induced pluripotent stem cells (iPSCs) using protein-based methods.
Successfully treated cerebral palsy through Korea's first cord blood stem cell transplantation program.
Advanced Cell Therapy Development Programs

CHA Medical Group continues to develop innovative cell therapies targeting a wide range of diseases and conditions, including:

Pluripotent Stem Cell Programs
Stargardt Macular Degeneration
Age-Related Macular Degeneration
Adult Stem Cell Programs
Intermittent Claudication
Critical Limb Ischemia
Alzheimer's Disease
Stroke
Degenerative Disc Disease
Parkinson's Disease
Muscular Dystrophy
Immune Cell Therapy Programs
Recurrent Glioblastoma
Recurrent Ovarian Cancer
Cord Blood & Regenerative Medicine Leadership

Through its renowned cord blood banking programs, CHA Medical Group has become a global leader in stem cell preservation and regenerative medicine research. The group's scientific contributions have helped advance treatments for neurological disorders, retinal diseases, blood cancers, vascular conditions, and degenerative diseases.

Today, CHA continues to invest heavily in clinical research, translational medicine, and next-generation cell therapies, reinforcing its position as one of Asia's most influential healthcare and biotechnology organizations.